Global healthcare struggles with slow, expensive lab-based diagnostics, especially in remote areas. Chronic diseases are projected to rise by 57%, and the COVID-19 pandemic highlighted the need for faster, decentralized solutions. Delays in diagnosis lead to higher costs and poorer outcomes.
BioEclosion offers a handheld diagnostic device providing results in 10 minutes. The device requires no specialized equipment and operates wirelessly through a smartphone app. It empowers healthcare providers to make faster decisions by offering diagnostics at the patient’s side, improving response times and reducing reliance on traditional lab-based testing. The device serves multiple sectors, from healthcare to food safety.
- Pilots: –
- Maturity: Development
- Capital raised: 800k €
- Company Valuation: 2.8 M€
- Open Round: No
The technology is built around a magnetic immunoassay system, capable of delivering sensitive and specific results from a drop of sample. The device uses a cartridge containing magnetic particles and conjugated antibodies, which, when connected wirelessly to a smartphone, provides rapid and accurate diagnostics. With eight hours of autonomy, the system is robust, user-friendly, and compliant with European IVDR Class A regulations.
- Sector: Health tech
- Country: Spain
- Nº of workers: 4
